Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101

Adenosine is a purine nucleoside that acts as a regulatory molecule by binding to specific G-protein-coupled A1, A 2A , A 2B , and A3 cell surface receptors. We have recently demonstrated that adenosine inhibits tumour cell growth and concomitantly stimulates bone marrow cell proliferation via activ...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2003-10, Vol.89 (8), p.1552-1558
Main Authors: Ohana, G, Bar-Yehuda, S, Arich, A, Madi, L, Dreznick, Z, Rath-Wolfson, L, Silberman, D, Slosman, G, Fishman, P
Format: Article
Language:English
Subjects:
Adenosine
Adenosine - analogs & derivatives
Adenosine - pharmacology
Administration, Oral
Animals
Antineoplastic agents
Bioavailability
Biological and medical sciences
Biological Availability
Biomedical and Life Sciences
Biomedicine
Bone marrow
Cancer Research
Cancer therapies
Carcinoma - secondary
Cell cycle
Cell Division - drug effects
Cell growth
Chemotherapy
Colon
Colonic Neoplasms - pathology
Disease Models, Animal
Drug Resistance
Epidemiology
Experimental Therapeutics
Humans
Kinases
Liver Neoplasms - secondary
Medical research
Medical sciences
Melanoma
Metastasis
Mice
Mice, Inbred BALB C
Molecular Medicine
Oncology
Pharmacology. Drug treatments
Proteins
Purinergic P1 Receptor Agonists
Signal transduction
Transplantation, Heterologous
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adenosine is a purine nucleoside that acts as a regulatory molecule by binding to specific G-protein-coupled A1, A 2A , A 2B , and A3 cell surface receptors. We have recently demonstrated that adenosine inhibits tumour cell growth and concomitantly stimulates bone marrow cell proliferation via activation of the A3 adenosine receptor (A3AR). In the present study, we show that a synthetic agonist to the A3AR, CF101, at the low nanomolar concentration range, inhibits HCT-116 human colon carcinoma cell growth. This effect was reversed by the selective A3AR antagonist MRS1523, demonstrating the specificity of the response. CF101 (given orally) was efficacious in inhibiting the development of primary tumours in xenograft and syngeneic models in which mice were inoculated subcutaneously with human HCT-116 or murine CT-26 colon carcinoma cells, respectively. Moreover, CF101 suppressed (50%, P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6601315